XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Clinical trial NCT05970302 · UNKNOWN

Trial details

NCT number: NCT05970302
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Tislelizumab Bevacizumab Oxaliplatin Capecitabine MSS/pMMR Metastatic Colorectal Cancer (mCRC)RAS-mutated First-Line

Start date: 2023-07-07
Primary completion: 2025-07-01
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.